Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subsetYuichiro Ohe, Kazuhiko Nakagawa, Andrew Walding et al.|Japanese Journal of Clinical Oncology|2018Cited by 153
Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastomaThomas C. Booth, Kevin M. Brindle, Holly C. Canuto et al.|PLoS ONE|2017Cited by 49
Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panelBenjamin Thomas, Hayley C. Whitaker, Jonathan D. Kay et al.|Endocrine Related Cancer|2016Cited by 13